# Azacytidine During Anti-tuberculosis Therapy

> **NCT03941496** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Andrew Dinardo**

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** Azacitidine Injection

## Key facts

- **NCT ID:** NCT03941496
- **Lead sponsor:** Andrew Dinardo
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10
- **Primary completion:** 2023-05
- **Final completion:** 2023-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941496, "Azacytidine During Anti-tuberculosis Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03941496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*